[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337454-105":59,"doc-detail-337454-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","molecular-genetic-profile-of-myelofibrosis-implications-in-the-diagnosis-prognosis-and-treatment-advancements","Molecular Genetic Profile of Myelofibrosis - Implications in the Diagnosis, Prognosis, and Treatment Advancements","","Myelofibrosis (MF) is presented as a central component of primary myelofibrosis and as a secondary manifestation in advanced myeloid neoplasms, notably polycythemia vera and essential thrombocythemia. Molecular advances over two decades, especially next-generation sequencing, have transformed diagnostic workflows and clinical decision making. Driver mutations in JAK2, CALR, and MPL activate the JAK-STAT pathway, while ~80% of cases carry additional alterations affecting epigenetic regulation, RNA splicing, and clonal evolution. Mutation profiling supports diagnosis, clonal mapping, prognostic scoring, and risk stratification. Standard JAK inhibitors improve symptoms for some patients, while limited molecular responses motivate trials combining epigenetic and immune or inflammatory modulators with JAK inhibitors, potentially benefiting high-risk mutation patterns.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/molecular-genetic-profile-of-myelofibrosis-implications-in-the-diagnosis-prognosis-and-treatment-advancements/337454/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/molecular-genetic-profile-of-myelofibrosis-implications-in-the-diagnosis-prognosis-and-treatment-advancements/337454.png","ImageObject",300,407,{"name":92,"@type":93},"Patrick","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What role do JAK2, CALR, and MPL mutations play in myelofibrosis?","Question",{"text":112,"@type":113},"They induce hyperactivity in the JAK-STAT signaling pathway, which is central to cell survival and proliferation, contributing to disease biology in myelofibrosis.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why is next-generation sequencing important for myelofibrosis diagnosis and classification?",{"text":117,"@type":113},"Integrating next-generation sequencing into clinical laboratories has revolutionized how myelofibrosis is diagnosed, classified, and used to guide clinical decision making.",{"name":119,"@type":110,"acceptedAnswer":120},"How do additional mutations beyond JAK2, CALR, and MPL affect clinical interpretation?",{"text":121,"@type":113},"About 80% of cases carry additional mutations often involving epigenetic regulation and RNA splicing; detecting these changes is crucial for diagnosing MPNs, including triple-negative cases.",{"name":123,"@type":110,"acceptedAnswer":124},"What treatment approaches are highlighted, and why are new combinations being studied?",{"text":125,"@type":113},"JAK inhibitors are part of standard care, but only a minority achieve significant molecular-level responses. Clinical trials explore combinations with epigenetic-targeting agents and immune or inflammatory modulators to improve outcomes, especially in patients with complex or high-risk mutation profiles.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},337454,1790721822,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","cancers   \nReview  \nMolecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements  \nTanvi Verma 1, Nikolaos Papadantonakis 2, Deniz Peker Barclift 1 and Linsheng Zhang 1, *  \nCitation: Verma, T.; Papadantonakis, N.; Peker Barclift, D.; Zhang, L. Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements. Cancers 2024, 16, 514 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)cancers16030514  \nAcademic Editor: Jonas Cicenas  \nReceived: 30 December 2023  \nRevised: 22 January 2024  \nAccepted: 23 January 2024  \nPublished: 25 January 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA  \n2 Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA  \n* Correspondence: [linsheng.zhang@emory.edu](linsheng.zhang@emory.edu)  \nSimple Summary: Myelofibrosis refers to fibrosis in the bone marrow associated with certain bone marrow cancers. It is a characteristic of primary myelofibrosis and may develop later in other bone marrow cancers with overproduction of blood cells, such as polycythemia vera and essential thrombocythemia. It has been confirmed that mutations in three key genes, Janus kinase 2 (JAK2), calreticulin (CALR), and myeloproliferative leukemia oncogene (MPL), can increase the activity of blood-producing cells, make them grow more actively, and are associated with the development of myelofibrosis. Approximately 80% of myelofibrosis cases carry additional mutations that often involve proteins that control how genes are turned on and off. The presence of mutations provides evidence of a cancerous process. The order in which these mutations occur can influence how the disease manifests. Studies have shown that fibrosis is secondary to the cancerous process and is closely linked to abnormal cell growth driven by mutations. Sophisticated scoring systems have been developed to guide treatment decisions. Specific mutations and genetic changes significantly affect the scores and survival of individual patients. Currently, common treatment involves JAK inhibitors, which can help improve clinical symptoms; however, only a small number of patients show significant alleviation in the biology of the malignant process. New treatments being explored in clinical trials include drugs that target the regulation of genes and substances that modulate the immune system or inflammatory processes. Combining these with JAK inhibitors shows promising results, especially in patients with complex genetic profiles. In the future, by studying more genes, it is expected that researchers will uncover the reasons behind cases where mutations are not found in the three key genes and understand how genetic changes are connected to variable disease presentations, ultimately guiding personalized treatment plans for better outcomes with a chance for cures.  \nAbstract: Myelofibrosis (MF) is an essential element of primary myelofibrosis, whereas secondary MF may develop in the advanced stages of other myeloid neoplasms, especially polycythemia vera and essential thrombocythemia. Over the last two decades, advances in molecular diagnostic techniques, particularly the integration of next-generation sequencing in clinical laboratories, have revolutionized the diagnosis, classification, and clinical decision making of myelofibrosis. Driver mutations involving JAK2, CALR, and MPL induce hyperactivity in the JAK-STAT signaling pathway, which plays a central role","cbCaiqtXlkiGGxHr","https://ap.wps.com/l/cbCaiqtXlkiGGxHr","pdf",1967773,27,"English","# Abstract\n## Molecular diagnostics and driver mutations\n## Mutation profiling, clonal evolution, and diagnosis\n## Prognostic scoring and risk stratification\n## Treatment landscape and emerging combination therapies","[{\"question\":\"What role do JAK2, CALR, and MPL mutations play in myelofibrosis?\",\"answer\":\"They induce hyperactivity in the JAK-STAT signaling pathway, which is central to cell survival and proliferation, contributing to disease biology in myelofibrosis.\"},{\"question\":\"Why is next-generation sequencing important for myelofibrosis diagnosis and classification?\",\"answer\":\"Integrating next-generation sequencing into clinical laboratories has revolutionized how myelofibrosis is diagnosed, classified, and used to guide clinical decision making.\"},{\"question\":\"How do additional mutations beyond JAK2, CALR, and MPL affect clinical interpretation?\",\"answer\":\"About 80% of cases carry additional mutations often involving epigenetic regulation and RNA splicing; detecting these changes is crucial for diagnosing MPNs, including triple-negative cases.\"},{\"question\":\"What treatment approaches are highlighted, and why are new combinations being studied?\",\"answer\":\"JAK inhibitors are part of standard care, but only a minority achieve significant molecular-level responses. Clinical trials explore combinations with epigenetic-targeting agents and immune or inflammatory modulators to improve outcomes, especially in patients with complex or high-risk mutation profiles.\"}]","Molecular Genetic Profile of Myelofibrosis - Implications in the Diagnosis, Prognosis, and Treatment Advancements | PDF",1790019212,68,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/11b12afe2ee4756758beef9b8a20d02e.webp",983,1390,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/63d46a35b326456d1bf0ee88c9dfe53e.webp",982,1388,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1803b4388801105a6479827a87206cf7.webp",981,1387,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4d86901cd58f3c4eb0b2b84b4ce3ece4.webp",980,1385]